Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06789757 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

Study acronym: (HCC)
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Oct 27, 2025 to Oct 27, 2026
    • Study sites: 1 to 2
    • Study completion date: Jan 27, 2027 to Jan 27, 2028
    v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 27, 2025 to Feb 25, 2025
    • Site details revised
    v4
  3. Start date: Jan 27, 2025 to Apr 27, 2025
    • Primary completion date: Jun 27, 2025 to Oct 27, 2025
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.
Trial Details
NCT Number NCT06789757
Lead Sponsor Inova Health Care Services
Conditions
(from sponsor)		 Hepatocellular Carcinoma
Related terms Carcinoma, Hepatocellular
Enrollment 19 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov